Polaryx Q3 10-Q: Going Concern Reaffirmed, $8.4M Cash Funds Operations Only Through Q1 2027
PLYX is trading near its 52-week low of $1.69 (8.9% above the low) on light trading volume (0.2× avg).
Summary
Polaryx reported $8.4 million of cash as of September 30, 2026 — enough to fund operations only through Q1 2027 — and reiterated going-concern doubt while quarterly R&D spending jumped to $2.5 million on SOTERIA trial costs.
Key Events · Earnings and Guidance · PLYX
-
Going Concern Doubt Reaffirmed
The 10-Q states conditions 'raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.'
-
Cash Runway Ends Q1 2027
Cash and cash equivalents were $8.4 million at September 30, 2026; management estimates this funds operating expenses and capital expenditures only through the first quarter of 2027.
-
Cash Burn Accelerates on Trial Costs
Operating cash use was $6.5 million for the nine months ended September 30, 2026 versus $2.5 million a year earlier; Q3 R&D rose to $2.5 million from $514 thousand, including $2.0 million of SOTERIA CRO expense.
-
May 2026 Raise Largely Consumed
The company issued 2,502,696 shares at an average $4.00 per share for $10.0 million gross ($169 thousand offering costs) in May 2026 — the main source of the current cash balance.
Analysis · PLYX · Life Sciences
With $8.4 million in cash at September 30, Polaryx says it can fund operations only through the first quarter of 2027 — roughly one quarter of runway — and formally repeats that conditions raise substantial doubt about its ability to continue as a going concern. The burn is accelerating as the SOTERIA trial ramps: operating cash use was $6.5 million in the first nine months versus $2.5 million a year earlier, and third-quarter R&D jumped to $2.5 million from $514 thousand on $2.0 million of CRO costs. Another raise is therefore effectively required within months, and the May 2026 equity sale (2.5 million shares at $4.00 for $10.0 million) is already largely spent. The offsetting positive is that trial spending is going into the clinic rather than overhead, but shareholders face near-certain further dilution at whatever price the market offers.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLYX was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.7M. The 52-week trading range was $1.69 to $48.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.